

Applicant : Tamar H. Michaeli
Serial No. : 10/085,849
Filed : February 27, 2002
Page 2

Claim Amendments

Additions are underlined, deletions are struck through.

1-9 (canceled)

10 (currently amended) A method of increasing glucose dependent insulin secretion in a pancreatic β -cell in a mammal, where the mammal is in need of increased glucose dependent insulin secretion, the method comprising administering treating the β -cell with an selective inhibitor of phosphodiesterase 1C to the mammal.

11 (currently amended) The method of claim 10, wherein the inhibitor is an isobutylmethylxanthine ~~derivative~~ with substitutions consisting of a moiety at positions 2 (R1) and 8 (R2) independently selected from the group consisting of an alkyl (C₁ to C₃), a flouroalkyl (F₁ to F₃), a chloroalkyl (Cl₁ to Cl₃), an aryl (C₅ to C₆), a fluoroaryl (F₁ to F₂), and a chloroaryl (Cl₁ to Cl₂).

12 (cancelled)

13 (currently amended) The method of claim 10, wherein the inhibitor is selected from the group consisting of ~~IBMX~~, zaprinast, 8-methoxymethyl-1-methyl-3-(2-methylpropyl)xanthine (8MM-IBMX), vinpocetine, rolipram, milrinone, and combinations thereof.

14 (previously added) The method of claim 13, wherein the inhibitor is zaprinast.

15 (previously added) The method of claim 13, wherein the inhibitor is 8-methoxymethyl-1-methyl-3-(2-methylpropyl)xanthine (8MM-IBMX).

16 (previously added) The method of claim 10, wherein the mammal is a human.

17 (previously added) The method of claim 10, wherein the inhibitor is administered in an amount effective to regulate blood sugar levels in the mammal.

18 (previously added) The method of claim 10, wherein the inhibitor is administered orally.

Applicant : Tamar H. Michaeli

Serial No. : 10/085,849

Filed : February 27, 2002

Page 3

19 (previously added) The method of claim 10, wherein the inhibitor is administered in combination with an anti-diabetic agent selected from the group consisting of insulin, a sulfonylurea, and a biguanide.